Clinical Trials
91 trialsNCT05100862 2026-05-27
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT05675410 2026-05-27
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06337318 2026-05-27
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06973187 2026-05-27
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3 Recruiting
NCT07277231 2026-05-27
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT06136559 2026-05-26
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06943872 2026-05-26
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT03394365 2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT06717347 2026-05-22
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06742996 2026-05-22
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
Phase 3 Recruiting
NCT07215585 2026-05-22
SOUNDTRACK-D2
AstraZeneca
Phase 3 Recruiting
NCT07223021 2026-05-22
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT06549595 2026-05-20
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca
Phase 3 Recruiting
NCT06911502 2026-05-20
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT04269902 2026-05-19
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06091254 2026-05-19
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT05947851 2026-05-18
BELLWAVE-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06091865 2026-05-15
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06724237 2026-05-15
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT07342478 2026-05-14
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Phase 3 Recruiting
NCT07582432 2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3 Recruiting
NCT05018520 2026-05-11
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital
Phase 3 Recruiting
NCT06846671 2026-05-11
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT06970743 2026-05-11
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT01804686 2026-05-08
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03150693 2026-05-08
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05976763 2026-05-08
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04043494 2026-05-06
LBL 2018
University Hospital Muenster
Phase 3 Recruiting
NCT06149286 2026-05-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-05-06
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT03959085 2026-05-05
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
NCT04307576 2026-05-05
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT06084936 2026-05-04
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06051409 2026-04-30
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT06784752 2026-04-30
NETTER-3
Novartis
Phase 3 Recruiting
NCT03823534 2026-04-22
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
Phase 3 Recruiting
NCT04094311 2026-04-20
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT05254743 2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT06716814 2026-04-20
LIBERTY
Swedish Orphan Biovitrum
Phase 3 Recruiting
NCT05327894 2026-04-13
Interfant-21
Princess Maxima Center for Pediatric Oncology
Phase 3 Recruiting
NCT05645107 2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3 Recruiting
NCT06428019 2026-04-09
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT06470451 2026-04-03
FLASH2
Soligenix
Phase 3 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT07300514 2026-03-31
T-START-M1
Fudan University
Phase 3 Recruiting
NCT04685616 2026-03-30
RADAR
University College, London
Phase 3 Recruiting
NCT07139873 2026-03-27
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting